187 related articles for article (PubMed ID: 11863116)
1. Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing.
Baselga J
Ann Oncol; 2002 Jan; 13(1):8-9. PubMed ID: 11863116
[No Abstract] [Full Text] [Related]
2. The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors.
Slamon DJ
Oncologist; 2004; 9 Suppl 3():1-3. PubMed ID: 15163840
[No Abstract] [Full Text] [Related]
3. Lapatinib: a sword with two edges.
Kopper L
Pathol Oncol Res; 2008 Mar; 14(1):1-8. PubMed ID: 18409020
[TBL] [Abstract][Full Text] [Related]
4. HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer.
Arteaga CL; Moulder SL; Yakes FM
Semin Oncol; 2002 Jun; 29(3 Suppl 11):4-10. PubMed ID: 12138392
[TBL] [Abstract][Full Text] [Related]
5. The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.
Dragowska WH; Weppler SA; Qadir MA; Wong LY; Franssen Y; Baker JH; Kapanen AI; Kierkels GJ; Masin D; Minchinton AI; Gelmon KA; Bally MB
BMC Cancer; 2011 Oct; 11():420. PubMed ID: 21961653
[TBL] [Abstract][Full Text] [Related]
6. A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer.
Arteaga CL; O'Neill A; Moulder SL; Pins M; Sparano JA; Sledge GW; Davidson NE
Clin Cancer Res; 2008 Oct; 14(19):6277-83. PubMed ID: 18829509
[TBL] [Abstract][Full Text] [Related]
7. A Phase I/II Trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2).
Moulder SL; Arteaga CL
Clin Breast Cancer; 2003 Jun; 4(2):142-5. PubMed ID: 12864943
[No Abstract] [Full Text] [Related]
8. ECOG E1100: a phase II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpress HER2/neu (erbB-2).
Clin Adv Hematol Oncol; 2003 Apr; 1(4):237. PubMed ID: 16224413
[No Abstract] [Full Text] [Related]
9. Hints of future progress for HER-2 breast cancer.
Twombly R
J Natl Cancer Inst; 2011 Apr; 103(7):535-7. PubMed ID: 21436059
[No Abstract] [Full Text] [Related]
10. [Targeting ErbB receptors in breast cancer].
Fumoleau P; Campone M; Coudert B; Mayer F; Favier L; Ferrant E
Bull Cancer; 2007; 94(7 Suppl):F147-70. PubMed ID: 17964992
[TBL] [Abstract][Full Text] [Related]
11. Early success of combined EGFR and Her2 receptor blockade as a clinical strategy in breast cancer.
Cancer Biol Ther; 2004 Jun; 3(6):490. PubMed ID: 15717407
[No Abstract] [Full Text] [Related]
12. [Her2 positive breast cancer: practices].
Campone M; Berton-Rigaud D; Bourbouloux E; Sophie S; Zanetti A; Frenel JS
Bull Cancer; 2011 Feb; 98(2):154-63. PubMed ID: 21591301
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
14. Updates on therapeutic approaches in HER2-positive disease.
Dickler MN
Clin Adv Hematol Oncol; 2010 Feb; 8(2):105-7. PubMed ID: 20386531
[No Abstract] [Full Text] [Related]
15. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.
Tuma RS
J Natl Cancer Inst; 2007 Mar; 99(5):348-9. PubMed ID: 17341725
[No Abstract] [Full Text] [Related]
16. Multitargeted therapy in estrogen receptor-positive, human epidermal growth factor receptor-2-positive breast cancer.
Nahleh ZA; Jazieh AR
Am J Clin Oncol; 2005 Dec; 28(6):631-3. PubMed ID: 16317277
[No Abstract] [Full Text] [Related]
17. New molecule-targeting therapy with herceptin (trastuzumab), an anti-HER2 (c-erB-2) monoclonal antibody.
Sakamoto G; Mitsuyama S
Breast Cancer; 2000; 7(4):350-7. PubMed ID: 11114864
[No Abstract] [Full Text] [Related]
18. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Cameron DA; Stein S
Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
[TBL] [Abstract][Full Text] [Related]
19. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction.
Warburton C; Dragowska WH; Gelmon K; Chia S; Yan H; Masin D; Denyssevych T; Wallis AE; Bally MB
Clin Cancer Res; 2004 Apr; 10(7):2512-24. PubMed ID: 15073131
[TBL] [Abstract][Full Text] [Related]
20. Development of new targeted therapies for breast cancer.
Doyle DM; Miller KD
Cancer Treat Res; 2008; 141():119-34. PubMed ID: 18274086
[No Abstract] [Full Text] [Related]
[Next] [New Search]